Finally, the data is in here at OZMOSI, and we can start tracking and reporting on the clinical development expected to come out of China. Gone are the days of developing drugs only in the US and then watching them slowly make their way to the rest of the world. China’s current trial pipeline below illustrates a disease area focus that is on par with what we see and expect from the US, EU, and Japan. And that’s only the beginning. China is now taking a very active role in developing novel therapies directly, and not just for their own [...]
About ozmosi_adminThis author has not yet filled in any details.
So far ozmosi_admin has created 21 blog entries.
Pharmaceutical companies are being pushed aside when it comes to who is driving clinical outcomes. Despite the growing number of industry trials year over year, the pharmaceutical industry is taking a back seat to the even faster growing hospital groups and universities in the same space. Looking back to the year 2000, 8 out of the top 10 clinical trial sponsors were large pharmaceutical companies. Historically, over the same time period, pharma companies accounted for more than 30% of all clinical trials. Today, not a single pharmaceutical company rises to the level of top 10 clinical trial sponsors, and they account [...]
For years, Eli Lilly’s main contributions to the Diabetes market were their insulins: fast acting analog Humalog® and human insulin Humalin and two premix offerings in analog Humalog® Mix 50/50 and human premix Humalin 75/25. Despite a legacy category, this portfolio of insulins continues to drive significant revenue with over $2.5 billion in Sales in 2016 alone. In the short acting market, Lilly’s Humalog® has competed primarily with Novo Nordisk’s NovoLog® with much of the battle between the two shifting from Sales Force to competing on PBM/payer access in recent years; physicians and patients do not see a whole lot of [...]
Novo Nordisk remains a top player in the Diabetes market with blockbuster insulins NovoLog® and Levemir® which brought in a combined almost $3.5 billion in 20166, Victoza® a GLP-1 that brought in $2.1 billion in 20166, and recently launched Basal insulin/GLP-1 combination product Xultophy®, which is expected to reach $1.2 billion in 2021.11 In the basal category, Novo Nordisk’s Levemir® has long been second to Sanofi’s Lantus, despite steadily increasing share over time. Hoping to break out in this category, in early 2016, Novo Nordisk launched Tresiba®, their next generation basal insulin to compete against Lantus® and Lantus’s successor Toujeo®. This [...]
Merck’s two blockbuster diabetes products, Janumet® and Januvia®, are DPP-4 inhibitors that generated nearly $3.3 billion in Sales in 2016.3 Januvia® is especially known for its great cardiovascular safety profile, which has helped differentiate itself in its class. But Merck has no plans of stopping there with four different products in late stage development that appear to be promising. In conjunction with Pfizer, the company recently filed NDAs for three SGLT-2 inhibitors based on their ertugliflozin molecule – one as a monotherapy, another in combination with Januvia® (sitagliptin) and the third a combination with metformin. Despite expectations to launch with three [...]
Diabetes is one of the most prevalent diseases in the U.S., afflicting over 29 million people across Type 1 and Type 2 patients, according to the CDC1 and represents over a $50 billion dollar industry2. Pharmaceutical companies are constantly racing to create the next market leader, and 2018 will be no exception. Diabetes is a very challenging market to compete in since there is intense pricing pressure as well as more recent pressures for stellar cardiovascular outcomes data. It is no longer sufficient to demonstrate superior efficacy compared to alternative treatments. Doctors and patients are looking for heightened safety profiles and [...]
In our previous post we described the technique for assigning categories to data, based on input from content experts within a “training database”. This technique is effective for summarizing large, text-heavy data into specific categories for summaries and improved visualization. While this approach is useful for those purposes, it will not allow us to uncover new insights or trends because we are imposing a preconceived and finite set of options, or in other words, what we already know. The following describes our approach to using clustering techniques for exploring text-heavy data. We applied this technique to two different datasets: scientific journals [...]
One of the most common and powerful approaches in NLP provides the content experts an opportunity to label each data segment for a portion of the dataset and then analyze these labels to apply to the rest of the dataset. Some key questions need to be answered when applying this approach in different environments. For example, how many “expert” labels do we need to create before the classification works effectively? How can we evaluate this in advance? Are we limiting ourselves to only extracting from the data what we already believe to be true? We will discuss that last one in [...]
The problem with Big Data is that it is so Big! This issue is especially true in the world of healthcare and drug development. It is difficult to see across all the good clinical/scientific work going on around the world and understand exactly where we are headed and how we will get there for any given disease area. It’s about time we move from manually tackling the pharmaceutical data to using the power of natural language processing (NLP) and machine learning. NLP is at its early stage in the pharma industry and brings a strong potential to find trends and insights [...]
Ozmosi has been on a purpose-driven hiatus peppered with innovation, development and growth. In less than one year, we have compiled the world’s largest free comprehensive global clinical trial database, as well as an intuitive tool that enables effective and efficient analytic management. The free data base will be available to the public in the next couple of weeks and we are proud to provide it, because we believe that free data should be free. Our rapid expansion in capabilities has prompted the hire of a Natural Language Processing Specialist and a Client Service Director. This labor-intensive collaboration has brought the [...]